The medicine industry is booming, thanks to new technologies like bendable batteries and injectable bandages. While these new discoveries can treat cancer and repair organs, some researchers are working on improving older remedies. The US National Institutes of Health and Sanofi have combined antibodies into tri-specific antibodies targeting HIV infection.
“They are more potent and have greater breadth than any single naturally occurring antibody that’s been discovered.” [said Dr. Gary Nabel of Sanofi.]
“We’re getting 99% coverage, and getting coverage at very low concentrations of the antibody,”
HIV strains mutate faster than immune systems can adapt, making resistance almost futile. Animal trials saw a 100% success rate in monkeys, while human trials will begin next year.
“Combinations of antibodies that each bind to a distinct site on HIV may best overcome the defences of the virus in the effort to achieve effective antibody-based treatment and prevention.”
Further testing may prove the usefulness of tri-specific antibodies in other fields. The battle against HIV is far from over, but it’s safe to say we’re getting there, one antibody at a time.